134 related articles for article (PubMed ID: 12224817)
1. Angiotensin-converting enzyme activity is involved in the mechanism of increased endogenous nitric oxide synthase inhibitor in patients with type 2 diabetes mellitus.
Ito A; Egashira K; Narishige T; Muramatsu K; Takeshita A
Circ J; 2002 Sep; 66(9):811-5. PubMed ID: 12224817
[TBL] [Abstract][Full Text] [Related]
2. Renin-angiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension.
Ito A; Egashira K; Narishige T; Muramatsu K; Takeshita A
Jpn Circ J; 2001 Sep; 65(9):775-8. PubMed ID: 11548874
[TBL] [Abstract][Full Text] [Related]
3. Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress.
Suda O; Tsutsui M; Morishita T; Tasaki H; Ueno S; Nakata S; Tsujimoto T; Toyohira Y; Hayashida Y; Sasaguri Y; Ueta Y; Nakashima Y; Yanagihara N
Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1682-8. PubMed ID: 15217805
[TBL] [Abstract][Full Text] [Related]
4. Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X.
Chen JW; Hsu NW; Wu TC; Lin SJ; Chang MS
Am J Cardiol; 2002 Nov; 90(9):974-82. PubMed ID: 12398965
[TBL] [Abstract][Full Text] [Related]
5. Perindopril alters vascular angiotensin-converting enzyme, AT(1) receptor, and nitric oxide synthase expression in patients with coronary heart disease.
Zhuo JL; Mendelsohn FA; Ohishi M
Hypertension; 2002 Feb; 39(2 Pt 2):634-8. PubMed ID: 11882622
[TBL] [Abstract][Full Text] [Related]
6. Effect of diabetic duration on serum concentrations of endogenous inhibitor of nitric oxide synthase in patients and rats with diabetes.
Xiong Y; Lei M; Fu S; Fu Y
Life Sci; 2005 May; 77(2):149-59. PubMed ID: 15862600
[TBL] [Abstract][Full Text] [Related]
7. Plasma angiotensin II, renin activity and serum angiotensin-converting enzyme activity in non-insulin dependent diabetes mellitus patients with diabetic nephropathy.
Nicola W; Sidhom G; El Khyat Z; Ibrahim S; Salah A; El Sayed A
Endocr J; 2001 Feb; 48(1):25-31. PubMed ID: 11403100
[TBL] [Abstract][Full Text] [Related]
8. Effect of angiotensin-converting enzyme inhibitor on serum asymmetric dimethylarginine and coronary circulation in patients with type 2 diabetes mellitus.
Kawata T; Daimon M; Hasegawa R; Teramoto K; Toyoda T; Sekine T; Yamamoto K; Uchida D; Himi T; Yoshida K; Komuro I
Int J Cardiol; 2009 Feb; 132(2):286-8. PubMed ID: 18083252
[TBL] [Abstract][Full Text] [Related]
9. Insight into the mode of action of ACE inhibition in coronary artery disease: the ultimate 'EUROPA' story.
Ferrari R; Fox K
Drugs; 2009; 69(3):265-77. PubMed ID: 19275271
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin converting enzyme inhibitor restrains inflammation-induced vascular injury in mice.
Akishita M; Shirakami G; Iwai M; Wu L; Aoki M; Zhang L; Toba K; Horiuchi M
J Hypertens; 2001 Jun; 19(6):1083-8. PubMed ID: 11403357
[TBL] [Abstract][Full Text] [Related]
11. Effects of perindopril treatment on hemostatic function in patients with essential hypertension in relation to angiotensin converting enzyme (ACE) and plasminogen activator inhibitor-1 (PAI-1) gene polymorphisms.
Jastrzebskal M; Widecka K; Naruszewicz M; Ciechanowicz A; Janczak-Bazan A; Foltynska A; Goracy I; Chetstowski K; Wesotowska T
Nutr Metab Cardiovasc Dis; 2004 Oct; 14(5):259-69. PubMed ID: 15673060
[TBL] [Abstract][Full Text] [Related]
12. [Possible participation of angiotensin-converting enzyme and leukocyte elastase in the pathogenesis of insulin-independent diabetes mellitus].
Dotsenko VL; Demidova TIu; Neshkova EA; Ametov AS; Iarovaia GA
Vopr Med Khim; 1998; 44(2):203-12. PubMed ID: 9634724
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin-converting enzyme inhibition and angiogenesis in myocardium of obese Zucker rats.
Toblli JE; Cao G; DeRosa G; Di Gennaro F; Forcada P
Am J Hypertens; 2004 Feb; 17(2):172-80. PubMed ID: 14751661
[TBL] [Abstract][Full Text] [Related]
14. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT.
Ceconi C; Fox KM; Remme WJ; Simoons ML; Bertrand M; Parrinello G; Kluft C; Blann A; Cokkinos D; Ferrari R; ;
Cardiovasc Res; 2007 Jan; 73(1):237-46. PubMed ID: 17140552
[TBL] [Abstract][Full Text] [Related]
15. Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA).
Maas R
Vasc Med; 2005 Jul; 10 Suppl 1():S49-57. PubMed ID: 16444869
[TBL] [Abstract][Full Text] [Related]
16. [The hemostasis parameters and ACE gene polymorphism in patients with essential hypertension treated with perindopril].
Janczak-Bazan A
Ann Acad Med Stetin; 2006; 52(1):51-61; discussion 61-2. PubMed ID: 17131847
[TBL] [Abstract][Full Text] [Related]
17. Effects of perindopril on insulin sensitivity and plasma lipid profile in hypertensive non-insulin-dependent diabetic patients.
Bak JF; Gerdes LU; Sørensen NS; Pedersen O
Am J Med; 1992 Apr; 92(4B):69S-72S. PubMed ID: 1580283
[TBL] [Abstract][Full Text] [Related]
18. Autonomy of the renin system in type II diabetes mellitus: dietary sodium and renal hemodynamic responses to ACE inhibition.
De'Oliveira JM; Price DA; Fisher ND; Allan DR; McKnight JA; Williams GH; Hollenberg NK
Kidney Int; 1997 Sep; 52(3):771-7. PubMed ID: 9291199
[TBL] [Abstract][Full Text] [Related]
19. Association of endothelial dysfunction with cardiovascular risk factors and new-onset diabetes mellitus in patients with hypertension.
Triches CB; Mayer S; Quinto BMR; Batista MC; Zanella MT
J Clin Hypertens (Greenwich); 2018 May; 20(5):935-941. PubMed ID: 29604155
[TBL] [Abstract][Full Text] [Related]
20. Effect of nebivolol and metoprolol treatments on serum asymmetric dimethylarginine levels in hypertensive patients with type 2 diabetes mellitus.
Oğuz A; Uzunlulu M; Yorulmaz E; Yalçin Y; Hekim N; Fici F
Anadolu Kardiyol Derg; 2007 Dec; 7(4):383-7. PubMed ID: 18065333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
